Egle A - Search Results

1

Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.

Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN. Brachtl G, et al. Among authors: egle a. PLoS One. 2011;6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18. PLoS One. 2011. PMID: 21876768 Free PMC article.

2

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Villunger A, et al. Among authors: egle a. Int J Cancer. 1996 Feb 8;65(4):498-505. doi: 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6. Int J Cancer. 1996. PMID: 8621234

3

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.

Egle A, Marschitz I, Posch B, Herold M, Greil R. Egle A, et al. Br J Haematol. 1996 Jul;94(1):211-2. Br J Haematol. 1996. PMID: 8757538 No abstract available.

4

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313

5

Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: egle a. Cancer Res. 1997 Aug 15;57(16):3331-4. Cancer Res. 1997. PMID: 9269989

6

Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.

Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 1998 Jun 1;91(11):4273-81. Blood. 1998. PMID: 9596676 Free article.

7

Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.

Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R. Villunger A, et al. Among authors: egle d, egle a. Br J Haematol. 1998 Sep;102(4):1069-80. doi: 10.1046/j.1365-2141.1998.00880.x. Br J Haematol. 1998. PMID: 9734660 Free article.

8

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil R, Egle A, Villunger A. Greil R, et al. Among authors: egle a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

9

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 2000 Jan 15;95(2):610-8. Blood. 2000. PMID: 10627470 Free article.

10

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.

Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R. Marschitz I, et al. Among authors: egle a. Am J Clin Pathol. 2000 Feb;113(2):219-29. doi: 10.1309/491W-L1TN-UFQX-T61B. Am J Clin Pathol. 2000. PMID: 10664624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters